Get started

Financials · CPIX

Cumberland Pharmaceuticals Inc. (CPIX) financials

For the twelve months ended Jun 30, 2026, Cumberland Pharmaceuticals Inc. reported $39.90M of revenue and -$10.92M of net income.

Revenue, TTM
$39.90M
Revenue growth, YoY
-5.2%
Net income, TTM
-$10.92M
Net margin
-27.4%
Free cash flow, TTM
$683.9K
EPS, diluted, TTM
-$0.73
Cash
$3.86M
P/S
2.02
Market cap
$80.5M
Annual revenue$44.52M
FY2016FY2025
Annual net income-$2.84M
FY2016FY2025
Annual free cash flow$4.83M
FY2016FY2025

CPIX revenue and earnings growth

CPIX revenueQ2 2026$8.80M

Quarter YoY
-18.8%
QoQ
-3.6%
FY YoY
+17.6%
5Y CAGR
+3.5%
10Y CAGR
+2.9%

CPIX revenue was $8.80M in fiscal Q2 2026 (ended Jun 30, 2026), down 18.8% from a year earlier and down 3.6% from the prior quarter. For the full fiscal 2025 it was $44.52M, up 17.6% from fiscal 2024. Compound annual growth was +3.5% over 5 years and +2.9% over 10 years. It rose in 5 of the last 10 fiscal years.

CPIX net incomeQ2 2026-$4.28M

CPIX net income was -$4.28M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$740.7K a year earlier. For the full fiscal 2025 it was -$2.84M, compared with -$6.48M in fiscal 2024.

CPIX EPSQ2 2026-$0.29

CPIX diluted EPS was -$0.29 in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$0.05 a year earlier. For the full fiscal 2025 it was -$0.19, compared with -$0.46 in fiscal 2024.

CPIX free cash flowQ2 2026$130.5K

Quarter YoY
-84.0%
QoQ
-66.3%
5Y CAGR
-1.7%
10Y CAGR
-1.7%

CPIX free cash flow was $130.5K in fiscal Q2 2026 (ended Jun 30, 2026), down 84.0% from a year earlier and down 66.3% from the prior quarter. For the full fiscal 2025 it was $4.83M, compared with -$678.6K in fiscal 2024. Compound annual growth was -1.7% over 5 years and -1.7% over 10 years.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue$44.52M$37.87M$39.55M$42.01M$35.99M$37.44M$34.39M$29.34M$41.15M$33.03M
Cost of revenue$6.67M$6.59M$6.07M$9.12M$8.81M$8.65M$7.42M$6.02M$7.37M$5.96M
Gross profit$37.85M$31.28M$33.49M$32.89M$27.17M$28.79M$26.97M$23.33M$33.78M$27.07M
Research and development$5.57M$4.82M$5.83M$6.69M$5.68M$5.77M$6.87M$7.58M$4.28M$3.19M
Selling, general and admin$11.95M$11.13M$10.65M$10.18M$9.78M$10.20M$9.97M$10.15M$9.65M$8.56M
Operating income-$2.79M-$6.43M-$9.55M-$5.70M-$7.68M-$6.38M-$9.29M-$11.17M-$4.08M-$1.43M
Interest expense$496.0K$605.5K$667.9K$586.0K$98.0K$263.6K$246.2K$195.8K$92.9K$106.4K
Pre-tax income-$2.81M-$6.47M-$6.28M-$5.58M-$5.56M-$6.57M-$9.29M-$10.80M-$3.87M-$1.33M
Income tax$40.3K-$22.7K$45.8K$68.8K$34.9K$55.9K-$79.3K$16.6K$4.17M-$330.9K
Net income-$2.84M-$6.48M-$6.28M-$5.57M-$3.51M-$3.34M-$3.54M-$6.96M-$7.98M-$944.7K
EPS, basic-$0.19-$0.46-$0.44-$0.38-$0.24-$0.22-$0.23-$0.45-$0.50-$0.06
EPS, diluted-$0.19-$0.46-$0.44-$0.38-$0.24-$0.22-$0.23-$0.45-$0.50-$0.06
Diluted shares14.9M14.1M14.3M14.6M14.9M15.2M15.4M15.6M15.9M16.2M

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Cash and equivalents$11.44M$17.96M$18.32M$19.76M$27.04M$24.75M$28.21M$27.94M$45.41M$34.51M
Short-term investments------$0$8.29M$4.67M$15.62M
Receivables$16.94M$11.70M$9.76M$13.16M$6.88M$12.38M$7.86M$7.84M$8.40M$7.33M
Inventory$29.9K$4.00M$4.61M$9.86M$8.43M$10.64M$8.87M$12.08M$6.74M$5.37M
Current assets$37.06M$36.45M$35.71M$45.87M$45.69M$49.97M$50.16M$59.12M$68.68M$65.55M
Goodwill$914.0K$914.0K$914.0K$914.0K$882.0K$882.0K$882.0K$784.0K$0-
Total assets$76.82M$75.58M$81.78M$92.93M$84.46M$96.46M$104.55M$112.69M$93.23M$93.40M
Current liabilities$36.74M$31.62M$27.98M$28.58M$19.28M$25.67M$24.15M$27.80M$17.69M$14.79M
Short-term debt$0$5.10M$0-------
Total liabilities$52.28M$53.04M$52.52M$56.95M$41.86M$49.59M$53.46M$57.12M$29.31M$20.28M
Shareholders' equity$24.88M$22.55M$29.26M$35.97M$42.60M$46.87M$51.09M$55.57M$63.92M$73.12M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Operating cash flow$4.93M-$612.2K$6.09M$8.45M$6.34M$5.42M$3.06M$3.11M-$557.7K$569.5K
Capital expenditures$97.9K$66.5K$281.3K$102.1K$103.5K$140.8K$246.2K$455.6K$276.0K$130.9K
Free cash flow$4.83M-$678.6K$5.81M$8.35M$6.24M$5.27M$2.81M$2.66M-$833.7K$438.6K
Investing cash flow-$4.71M$57.8K-$105.7K-$13.67M-$501.9K-$1.76M$2.30M-$27.72M$9.51M-$3.12M
Financing cash flow-$6.75M$196.9K-$7.42M-$2.06M-$3.55M-$7.12M-$5.08M$7.14M$1.95M-$1.15M
Share repurchases$263.5K$579.0K$740.5K$1.05M$1.39M$1.85M$3.49M$2.88M$3.72M$2.52M
Stock-based compensation$408.3K$301.9K$365.0K$447.5K$741.9K$1.05M$1.49M$1.36M$1.12M$852.1K
Depreciation and amortization$4.15M$4.90M$4.94M$5.33M$4.61M$4.75M$4.40M$2.98M$2.65M$2.40M

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue growth, YoY17.6%-4.3%-5.9%16.7%-3.9%8.9%17.2%-28.7%24.6%-1.5%
Gross margin85.0%82.6%84.7%78.3%75.5%76.9%78.4%79.5%82.1%82.0%
Operating margin-6.3%-17.0%-24.2%-13.6%-21.3%-17.0%-27.0%-38.1%-9.9%-4.3%
Net margin-6.4%-17.1%-15.9%-13.3%-9.7%-8.9%-10.3%-23.7%-19.4%-2.9%
Free cash flow margin10.9%-1.8%14.7%19.9%17.3%14.1%8.2%9.1%-2.0%1.3%
Return on equity-11.4%-28.7%-21.5%-15.5%-8.2%-7.1%-6.9%-12.5%-12.5%-1.3%
Return on assets-3.7%-8.6%-7.7%-6.0%-4.2%-3.5%-3.4%-6.2%-8.6%-1.0%
Current ratio1.011.151.281.602.371.952.082.133.884.43

Source: XBRL data Cumberland Pharmaceuticals Inc. files with the SEC, latest filing dated Aug 7, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

CPIX peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
CPIX$39.90M-5.2%-$10.92M-27.4%$80.5M
LLY$86.46B+45.5%$27.58B31.9%$1.33T
JNJ$99.33B+7.8%$16.09B16.2%$679.13B
ABBV$66.01B+10.7%$10.34B15.7%$518.44B
MRK$67.38B+4.9%$2.45B3.6%$366.73B
NVS$54.53B+8.4%$13.98B25.6%$312.35B
AZN$58.74B+8.6%$10.22B17.4%$293.69B
ABT$48.23B+10.0%$4.70B9.7%$191.40B
NVODKK 309.06B+6.4%DKK 102.43B33.1%$183.23B

CPIX FAQ

8 questions
  • What is CPIX revenue?
    Cumberland Pharmaceuticals Inc. (CPIX) reported $39.90M of revenue for the twelve months ended Jun 30, 2026. That is down 5.2% from the year before. Revenue for fiscal 2025 was $44.52M.
  • Is CPIX profitable?
    No. Cumberland Pharmaceuticals Inc. reported a net loss of $10.92M for the twelve months ended Jun 30, 2026.
  • How much cash and debt does CPIX have?
    Cumberland Pharmaceuticals Inc. reported $3.86M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is CPIX revenue growing?
    Cumberland Pharmaceuticals Inc.'s revenue changed +17.6% in fiscal 2025, to $44.52M. Its compound annual growth rate was +3.5% over 5 years and +2.9% over 10 years.
  • What is CPIX free cash flow?
    Cumberland Pharmaceuticals Inc. generated $683.9K of free cash flow for the twelve months ended Jun 30, 2026, which is operating cash flow of $746.0K less capital expenditures.
  • What is CPIX earnings per share?
    Diluted earnings per share were -$0.73 for the twelve months ended Jun 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did CPIX last report financial results?
    The latest statements here come from Cumberland Pharmaceuticals Inc.'s 10-Q filed on Aug 7, 2026, covering the period ended Jun 30, 2026.
  • Where does this CPIX financial data come from?
    Quantisnow builds these statements from the structured XBRL data Cumberland Pharmaceuticals Inc. files with the SEC. It is provided for information only and is not investment advice.